ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a loan facility agreement with Oxford Finance LLC and Silicon Valley Bank for up to $100 million of non-dilutive financing.

Related Keywords

Alexandria ,Al Iskandariyah ,Egypt ,New York ,United States ,Boston ,Massachusetts ,California ,Virginia ,Palo Alto ,Christophera Herr ,Los Angeles ,Peter Garcia ,Kale Frank ,Silicon Valley Bank ,Oxford Finance ,Oncology Holdings Inc ,Holdings Inc ,Silicon Valley ,Chief Financial Officer ,Senior Managing Director ,Valley Bank ,Life Science ,San Diego ,New York City ,Alliance ,Banking ,Cancer ,Cancer Research ,Forward Looking Statement ,Healthcare ,Medical Specialties ,Medicine ,Oncology ,Partnership ,Venture Capital ,Cancer Immunotherapy ,Cd47 ,